Citations

Clear

3314 citation(s) found for "Do, Alexander".

CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL
Rahman, Rifaquat , Trippa, Lorenzo , Fell, Geoffrey, Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , McCluskey, Christine , Brunno, Jennifer, Gaffey, Sarah, Lassman, Andrew B. , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Haas‐Kogan, Daphne A. , Cagney, Daniel , Aizer, Ayal A. , Welch, Mary , Doherty, Lisa, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Watkinson, Fiona , Reardon, David A. , Wen, Patrick Y. , Ahluwalia, Manmeet S , Fell, Geoffrey G. , Arrillaga‐Romany, Isabel , Touat, Mehdi , Drappatz, Jan , Galanis, Evanthia , Colman, Howard , Nabors, Burt , Beroukhim, Rameen , McFaline-Figueroa, J Ricardo , Kaley, Thomas , Bi, Wenya Linda , Arnaout, Omar M. , Tanguturi, Shyam K , Geduldig, Jack , Santagata, Sandro , Meredith, David M. , Chiocca, E Antonio , Ligon, Keith L , Alexander, Brian M. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii43-ii44

10.1093/neuonc/noaa215.178 Get It

Abstract BACKGROUND CC-115 is an oral, CNS-penetrant, selective inhibitor of mammalian target of rapamycin kinase (mTOR) and deoxyribonucleic acid-dependent protein kinase (DNA-PK). Both targets are important in glioblastoma; PI3K/Akt/mTOR signaling is hyperactive in most glioblastomas, and DNA-PK is integral to repair of radiotherapy-mediated DNA damage. To investigate CC-115 in newly diagnosed glioblastoma and explore potential genomic biomarker associations, CC-115 was evaluated in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial, an adaptive platform trial designed to efficiently test experimental agents. METHODS Adults with newly diagnosed MGMT-unmethylated glioblastoma, with genomic data available, are eligible for this ongoing trial. Patients are adaptively randomized to one of several experimental arms or the control arm: standard radiotherapy with concurrent and adjuvant temozolomide. The primary endpoint is overall survival (OS). Patients randomized to CC-115 (10mg po BID) received it concurrently with radiotherapy and as adjuvant monotherapy. As the first in-human use of CC-115 with radiation, a safety lead-in 3 + 3 design was used. RESULTS Twelve patients were randomized to CC-115; seven patients had possible treatment-related CTCAE grade > 3 toxicity, including four pre-specified dose-limiting toxicities: liver function abnormality (n=1), hyperlipidemia (n=1), lipase elevation (n=1) and cerebral edema (n=1). There was no significant difference in progression-free survival (PFS, median 4.2 months [CC-115] vs. 5.2 months, p=0.9) or OS (median 10.1 months [CC-115] vs. 14.5 months, p=0.9) compared to the 50 patients randomized to the control arm. Based on early PFS results, randomization probability to CC-115 decreased from 25% to < 10% at time of the trial arm closure. CONCLUSION Concurrent and adjuvant CC-115 was associated with toxicity and failed to improve PFS or OS. The INSIGhT trial design allowed for more efficient testing of CC-115, decreasing patients and resources allocated to a therapy that was discontinued due to concerns about toxicity and unfavorable risk-to-benefit ratio.
CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION
Wen, Patrick Y. , Trippa, Lorenzo , Lee, Eudocia Q. , Fell, Geoffrey, Rahman, Rifaquat , Arrillaga‐Romany, Isabel , McCluskey, Christine , Brunno, Jennifer, Gaffey, Sarah, Lassman, Andrew B. , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Doherty, Lisa, Haas‐Kogan, Daphne A. , Cagney, Daniel , Aizer, Ayal A. , Welch, Mary , Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Reardon, David A. , Ahluwalia, Manmeet S , Wen, Patrick Yung , Fell, Geoffrey G. , Arrillaga‐Romany, Isabel , Touat, Mehdi , Drappatz, Jan , Galanis, Evanthia , Colman, Howard , Nabors, Burt , Beroukhim, Rameen , McFaline-Figueroa, J Ricardo , Kaley, Thomas , Bi, Wenya Linda , Arnaout, Omar M. , Peruzzi, Pier Paolo , Tanguturi, Shyam K , Geduldig, Jack , Santagata, Sandro , Meredith, David M. , Chiocca, E Antonio , Ligon, Keith L , Alexander, Brian M.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii44-ii44

10.1093/neuonc/noaa215.179 Get It

Abstract BACKGROUND The cyclin D-CDK4/6-Rb pathway is activated in most glioblastomas. Abemaciclib is a potent CDK4/6 inhibitor with good brain penetration approved for ER/PR/HER2- breast cancer. In order to efficiently evaluate the potential impact of abemaciclib on overall survival (OS) in newly diagnosed glioblastoma and to simultaneously develop information regarding potential genomic biomarker associations, abemaciclib was included as an arm on the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial. INSIGhT is a phase II platform trial using response adaptive randomization and deep genomic profiling to more efficiently test experimental agents in MGMT unmethylated glioblastoma and potentially accelerate identification of novel therapies for phase III testing. Initial randomization was equal between abemaciclib, control, and two other experimental arms but subsequent randomization was adapted based on efficacy as determined by progression-free survival (PFS). Ineffective arms were discontinued and new arms added by protocol amendment. We report preliminary results for the abemaciclib arm which has completed accrual. METHODS Patients with newly diagnosed MGMT-unmethylated glioblastoma were randomized to receive either radiotherapy with concomitant and adjuvant temozolomide at standard doses or standard radiochemotherapy followed by adjuvant abemaciclib (150–200 mg orally BID) without temozolomide. Treatment continued until progression or development of unacceptable toxicities. The primary endpoint was OS. Association between abemaciclib efficacy and cyclin D-CDK4/6-Rb pathway genomic alterations was also investigated. RESULTS There were 123 patients (50 control; 73 treated with abemaciclib). Abemaciclib was generally well-tolerated with no new toxicity signals identified. PFS was significantly longer (p=0.03, logrank test) with abemaciclib (median 6.31 months 95% CI [5.29, 8.18]) compared to the control arm (5.16 months 95% CI [4.37, 6.28]). 28/50 control and 36/73 abemaciclib patients remain alive. CONCLUSION Preliminary analysis suggests that abemaciclib increases PFS compared to control. Updated toxicity, PFS and survival data and potential genomic biomarker associations will be presented.
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy
Biran, Anat, Purroy, Noelia, Lemvigh, Camilla K. , Clement, Kendell , Gruber, Michaela , Rassenti, Laura Z., Mohammad, Arman W., Lesnick, Connie , Shanafelt, Tait D. , Fernandes, Stacey M. , Brown, Jennifer R. , Wang, Lili , Li, Shuqiang , Livak, Kenneth J. , Klages, Sven , Timmermann, Bernd, Gnirke, Andreas , Wu, Catherine J. , Meissner, Alexander , Clement, Kendell , Gruber, Michaela , Kay, Neil E , Neuberg, Donna S , Campo, Elías , Wu, Catherine J , Shanafelt, Tait D , Kretzmer, Helene , Gu, Hongcang , Slager, Susan L. , Braggio, Esteban , Kay, Neil E. , Neuberg, Donna , Kipps, Thomas J. , Campo, Elı́as

Mayo Clinic

Blood Cancer Discovery | December 3, 2020 | Volume: 2 | Issue: 1 | Pages: 54-69

10.1158/2643-3230.bcd-19-0058 | PMID 33604581 Get It

Abstract Most human cancers converge to a deregulated methylome with reduced global levels and elevated methylation at select CpG islands. To investigate the emergence and dynamics of the cancer methylome, we characterized genome-wide DNA methylation in preneoplastic monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL), including serial samples collected across disease course. We detected the aberrant tumor-associated methylation landscape at CLL diagnosis and found no significant differentially methylated regions in the high-count MBL-to-CLL transition. Patient methylomes showed remarkable stability with natural disease and posttherapy progression. Single CLL cells were consistently aberrantly methylated, indicating a homogeneous transition to the altered epigenetic state and a distinct expression profile together with MBL cells compared with normal B cells. Our longitudinal analysis reveals the cancer methylome to emerge early, which may provide a platform for subsequent genetically driven growth dynamics, and, together with its persistent presence, suggests a central role in disease onset. Significance: DNA methylation data from a large cohort of patients with MBL and CLL show that epigenetic transformation emerges early and persists throughout disease stages with limited subsequent changes. Our results indicate an early role for this aberrant landscape in the normal-to-preneoplastic transition that may reflect a pan-cancer mechanism. See related commentary by Rossi, p. 6. This article is highlighted in the In This Issue feature, p. 1
Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients
Bryant, Laura , Li, Dong , Cox, Samuel G., Wilson, Khadija , Janssen, Kevin A. , March, Michael , Sherr, Elliott H. , Fregeau, Brieana, Wierenga, Klaas J. , Wadley, Alexandrea, Mancini, Grazia M.S., Powell‐Hamilton, Nina , Kamp, Jiddeke van de, Grebe, Theresa A., Ross, Alison , Crawford, Heather P., Powis, Zöe , Cho, Megan T. , Willing, Marcia, Schot, Rachel , Afenjar, Alexandra , Lessel, Davor , Wagner, Matias , Klopstock, Thomas , Winkelmann, Juliane , Retterer, Kyle , Schuette, Jane L., Innis, Jeffrey W. , Pizzino, Amy , Lüttgen, Sabine, Denecke, Jonas , Strom, Tim M., Monaghan, Kristin G. , Study, DDD, Yuan, Zuo‐Fei , Dubbs, Holly , Bend, Renee, Lee, Jennifer A. , Lyons, Michael J. , Hoefele, Julia , Günthner, Roman , Keren, Boris , Radtke, Kelly, Sherbini, Omar , Mrokse, Cameron, Helbig, Katherine L. , Odent, Sylvie , Mercier, Sandra , Küry, Sébastien , Redon, Richard , Reinson, Karit , Wojcik, Monica H. , Õunap, Katrin , Ilves, Pilvi , Innes, A. Micheil , Kernohan, Kristin D. , Costain, Gregory , Zackai, Elaine H. , Kitson, Hilary, Study, CAUSES, Martin, Martin G., Martínez-Agosto, Julián A. , Network, Undiagnosed Diseases, Nelson, Stan F., Palmer, Christina G.S. , Papp, Jeanette C. , Parker, Neil H., Wan, Jijun , Yoon, Amanda J., Zheng, Allison, Carli, Diana , Brusco, Alfredo , Tartaglia, Marco , Thomas, Jennifer Muncy, Weiss, Marjan M. , Gotway, Garrett , Stuurman, Kyra E. , Thompson, Michelle L. , Stumpel, Constance T. R. M., Stevens, Servi J.C. , Stegmann, Alexander P.A. , Tveten, Kristian , Vøllo, Arve, Prescott, Trine , Fagerberg, Christina , Laulund, Lone Walentin , Larsen, Martin J. , Byler, Melissa, Lebel, Robert Roger, Dean, Joy, Mercimek‐Andrews, Saadet , Neira, Juanita, Allen, Margot I. Van, Sellars, Elizabeth A. , Louie, Raymond J. , Cathey, Sara , Brokamp, Elly , Héron, Delphine, Snyder, Molly, Simon, Celeste, Cruz, Xavier de la , Padilla, Natàlia , García, Benjamin A. , Håkonarson, Håkon , Bhoj, Elizabeth , Nelson, Stanley F. , Sherr, Elliott , Dean, John , Lessel, Davor , Klopstock, Thomas , Kury, Sebastien , Brusco, Alfredo , McWalter, Kirsty , Stevens, Servi J C , Crump, J Gage , Hakonarson, Hakon , Bhoj, Elizabeth J , Tartaglia, Marco , Li, Dong , Wagner, Matias , Redon, Richard , Õunap, Katrin , de la Cruz, Xavier , Padilla, Natália , March, Michael , Hoefele, Julia , Marchione, Dylan M. , Joiner, Evan F. , Lee, Pearl , Nair, Divya, Kamp, Jiddeke M. van de , Manwaring, Linda P. , Nava, Caroline , Catarino, Claudia B. , Monaghan, Kristin G. , Study, DDD, Reutter, Heiko , Radtke, Kelly , Cogné, Benjamin , Bezieau, Stéphane , Besnard, Thomas , Meyn, M Stephen , Chitayat, David A. , Lehman, Anna , Study, CAUSES, Network, Undiagnosed Diseases, Sinsheimer, Janet S. , Vilain, Eric J. N. , Brimble, Elise , Ferrero, Giovanni Battista , Radio, Francesca Clementina , Barresi, Sabina , Umaña, Luis Alfredo , Hurst, Anna , Vergano, Samantha A. Schrier , Norman, Jennifer, Longo, Nicola , Vanderver, Adeline , Chung, Wendy K.

Mayo Clinic

Science Advances | December 3, 2020 | Volume: 6 | Issue: 49 | Pages: No page available

10.1126/sciadv.abc9207 | PMID 33268356 Get It

Germ line mutations in H3F3A and H3F3B cause a previously unidentified neurodevelopmental syndrome.
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Lefterova, Martina I., Artyomenko, Alexander , Kasi, Pashtoon Murtaza , Mody, Kabir , Catenacci, Daniel V.T. , Fakih, Marwan , Bárbácioru, Cátálin, Zhao, Jing , Fairclough, Stephen R. , Kim, Seung Tae , Kim, Jinchul , Gavino, Danielle , Benavides, Manuel , Peled, Nir , Nguyen, Timmy, Cusnir, Mike , Eskander, Ramez N. , Azzi, Georges, Banks, Kimberly C. , Chudova, Darya, Talasaz, AmirAli , Lee, Jeeyun , Odegaard, Justin I. , Artyomenko, Alexander , Kasi, Pashtoon Murtaza , Kim, Kyoung-Mee , Kim, Jinchul , Gavino, Danielle , Benavides, Manuel , Nguyen, Timmy , Cusnir, Mike , Banks, Kimberly C , Raymond, Victoria M , Lanman, Richard B , Odegaard, Justin I , Willis, Jason A. , Nakamura, Yoshiaki , Sikora, Marcin , Lee, Hyuk , Yoshino, Takayuki , Raymond, Victoria M. , Lanman, Richard B. , Kopetz, Scott , Fakih, Marwan

Mayo Clinic

Clinical Cancer Research | December 1, 2020 | Volume: 25 | Issue: 23 | Pages: 7035-7045

10.1158/1078-0432.ccr-19-1324 | PMID 31383735 Get It

AbstractPurpose:To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing.Experimental Design:Pan-cancer MSI detection using Guardant360 was analytically validated according to established guidelines and clinically validated using 1,145 cfDNA samples for which tissue MSI status based on standard-of-care tissue testing was available. The landscape of cfDNA-based MSI across solid tumor types was investigated in a cohort of 28,459 clinical plasma samples. Clinical outcomes for 16 patients with cfDNA MSI-H gastric cancer treated with immunotherapy were evaluated.Results:cfDNA MSI evaluation was shown to have high specificity, precision, and sensitivity, with a limit of detection of 0.1% tumor content. In evaluable patients, cfDNA testing accurately detected 87% (71/82) of tissue MSI-H and 99.5% of tissue microsatellite stable (863/867) for an overall accuracy of 98.4% (934/949) and a positive predictive value of 95% (71/75). Concordance of cfDNA MSI with tissue PCR and next-generation sequencing was significantly higher than IHC. Prevalence of cfDNA MSI for major cancer types was consistent with those reported for tissue. Finally, robust clinical activity of immunotherapy treatment was seen in patients with advanced gastric cancer positive for MSI by cfDNA, with 63% (10/16) of patients achieving complete or partial remission with sustained clinical benefit.Conclusions:cfDNA-based MSI detection using Guardant360 is highly concordant with tissue-based testing, enabling highly accurate detection of MSI status concurrent with comprehensive genomic profiling and expanding access to immunotherapy for patients with advanced cancer for whom current testing practices are inadequate.See related commentary by Wang and Ajani, p. 6887
Wnt/β-catenin activation epigenetically reprograms Regulatory T cells in IBD and progression to dysplasia.
Gounari, Fotini , Quandt, Jasmin , Arnovitz, Stephen , Haghi, Leila, Woehlk, Janine, Moshin, Azam, Emmanuel, Akinola Olumide , Osman, Abu , Krishnan, Manisha, Morin, Samuel B., Weber, Christopher, Khazaie, Khashayarsha , Gounari, Fotini , Mohsin, Azam , Okoreeh, Michael K. , Mathur, Priya, Pearson, Alexander T. , Sweis, Randy F. , Pekow, Joel

Mayo Clinic

No container title available | December 1, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-110212/v1 Get It

Abstract The molecular and functional diversity of regulatory T-cells (Tregs) in health and in disease remains unclear. We previously described in colorectal cancer (CRC) patients a subpopulation of RORγt+ Tregs with elevated expression of β-catenin and pro-inflammatory properties. Here we observed progressive expansion of RORγt+ Tregs in inflammatory bowel disease (IBD) patients during inflammation and early dysplasia. Activating Wnt/β-catenin signaling in human and murine Tregs was sufficient to recapitulate the disease-associated increase in frequencies of RORγt+ Tregs expressing IL-17, IFN-γ, and TNFa. We found that binding of the β-catenin interacting partner, TCF-1, to DNA overlapped with Foxp3 binding at enhancer sites of pro-inflammatory pathway genes. Sustained Wnt/β-catenin activation induced newly accessible chromatin sites in these genes and upregulated their expression. These findings indicate that TCF-1 and Foxp3 together limit the expression of pro-inflammatory genes in Tregs. Activation of ꞵ-catenin signaling interferes with this function and promotes the disease-associated RORγt+ Treg phenotype.
Potential Impact of the COVID‐19 Pandemic on Communication and Language Skills in Children
Charney, Sara , Chern, Alexander , Charney, Sara A, Camarata, Stephen

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 1, 2020 | Volume: 165 | Issue: 1 | Pages: 1-2

10.1177/0194599820978247 | PMID 33258739 Get It

The COVID‐19 pandemic has led to many unintended, long‐lasting consequences for society. Preventative practices such as mask wearing, social distancing, and virtual meetings and classrooms to address contagion concerns may negatively affect communication, particularly in the pediatric population, as schools have begun to open this fall. Increasing awareness and creating innovative methods to promote communication and language learning in settings both in person and virtual is paramount. Although more studies are needed to characterize the pandemic’s impact on pediatric speech and language development, clinicians and parents should be cognizant of this phenomenon and proactive in facilitating an optimal communication environment for children.
Brain volumetric deficits in MAPT mutation carriers: a multisite study
Chu, Stephanie A. , Flagan, Taru , Staffaroni, Adam M. , Jiskoot, Lize C. , Deng, Jersey, Sturm, Virginia E. , Yokoyama, Jennifer S. , Papma, Janne M. , Geschwind, Dan, Rosen, Howard J. , Boxer, Adam L. , Heuer, Hilary W. , Forsberg, Leah K. , Brushaber, Danielle , Coppola, Giovanni , Bordelon, Yvette , Faber, Kelley , Feldman, Howard , Fields, Julie A. , Gavrilova, Ralitza H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Kantarci, Kejal , Kaufer, Daniel , Karydas, Anna M., Kornak, John , Kramer, Joel H. , Kukull, Walter A. , Mackenzie, Ian R. , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Rademakers, Rosa , Ramos, Eliana Marisa , Roberson, Erik D. , Tartaglia, Maria Carmela , Tatton, Nadine , Toga, Arthur W. , Vetor, Ashley, Weıntraub, Sandra , Wong, Bonnie , Lee, Suzee E. , Brushaber, Danielle E, Kantarci, Kejal , Knopman, David S. , Lee, Suzee E , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Pantelyat, Alex , Tartaglia, Maria Carmela , Yokoyama, Jennifer , Feldman, Howard H , Jiskoot, Lize C , Spina, Salvatore , Zhang, Liwen , Seeley, William W. , Boeve, Bradley F. , Grossman, Murray , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Irwin, David J. , Knopman, David S. , Lapid, Maria I. , Litvan, Irene , Wszołek, Zbigniew K. , Swieten, John C. van

Mayo Clinic

Annals of Clinical and Translational Neurology | November 28, 2020 | Volume: 8 | Issue: 1 | Pages: 95-110

10.1002/acn3.51249 | PMID 33247623 Get It

AbstractObjectiveMAPT mutations typically cause behavioral variant frontotemporal dementia with or without parkinsonism. Previous studies have shown that symptomatic MAPT mutation carriers have frontotemporal atrophy, yet studies have shown mixed results as to whether presymptomatic carriers have low gray matter volumes. To elucidate whether presymptomatic carriers have lower structural brain volumes within regions atrophied during the symptomatic phase, we studied a large cohort of MAPT mutation carriers using a voxelwise approach.MethodsWe studied 22 symptomatic carriers (age 54.7 ± 9.1, 13 female) and 43 presymptomatic carriers (age 39.2 ± 10.4, 21 female). Symptomatic carriers’ clinical syndromes included: behavioral variant frontotemporal dementia (18), an amnestic dementia syndrome (2), Parkinson’s disease (1), and mild cognitive impairment (1). We performed voxel‐based morphometry on T1 images and assessed brain volumetrics by clinical subgroup, age, and mutation subtype.ResultsSymptomatic carriers showed gray matter atrophy in bilateral frontotemporal cortex, insula, and striatum, and white matter atrophy in bilateral corpus callosum and uncinate fasciculus. Approximately 20% of presymptomatic carriers had low gray matter volumes in bilateral hippocampus, amygdala, and lateral temporal cortex. Within these regions, low gray matter volumes emerged in a subset of presymptomatic carriers as early as their thirties. Low white matter volumes arose infrequently among presymptomatic carriers.InterpretationA subset of presymptomatic MAPT mutation carriers showed low volumes in mesial temporal lobe, the region ubiquitously atrophied in all symptomatic carriers. With each decade of age, an increasing percentage of presymptomatic carriers showed low mesial temporal volume, suggestive of early neurodegeneration.
Determinants of left ventricular hypertrophy and dysfunction in adults with coarctation of aorta
Egbe, A, Vojjini, Rahul , Banala, Keerthana, Egbe, Alexander C.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.2211 Get It

Abstract Background Several coarctation of aorta (COA) severity indices are used for timing of COA intervention, and to define severity of residual coarctation post-intervention. However, it is unclear how many of these COA indices are required in order to recommend intervention, and what degree of residual coarctation results in suboptimal recovery of the left ventricle (LV). Our aim was to assess the correlation between different COA indices and effects of chronic LV pressure overload (LV hypertrophy, diastolic and systolic dysfunction), and to determine the effect of residual coarctation on LV reverse remodeling after COA intervention. Methods COA severity indices were defined as Doppler COA gradient, systolic blood pressure, upper-to-lower-extremity systolic blood pressure gradient, aortic isthmus ratio. LV remodeling indices were defined as LV mass index (LVMI), LV global longitudinal strain (LVGLS), e' and E/e'. LV reverse remodeling was defined as the difference between indices obtained pre-intervention and 5-years post-intervention (delta LVMI, e', E/e', LVGLS). Results Of the COA indices analyzed in 546 adult COA patients, aortic isthmus ratio had the strongest correlation with LVMI (β±standard error −28.3±14.1, p<0.001), LVGLS (1.51±0.42, p=0.005), e' (3.11±1.10, p=0.014), and E/e' (−13.4±6.67, p=0.008). Residual aortic isthmus ratio also had the strongest correlation with LV reverse remodeling, and residual aortic isthmus ratio <0.7 was predictive of suboptimal LV reverse remodeling post-intervention. Conclusion Considering the known prognostic implications of LV remodeling and reverse remodeling in response to pressure overload, these results support the use of aortic isthmus ratio for timing of COA intervention, and for prognostication post-intervention. Funding Acknowledgement Type of funding source: None
Increased prevalence of left ventricular diastolic dysfunction in adults with coarctation of aorta
Egbe, A, Vojjini, Rahul , Banala, Keerthana, Egbe, Alexander C.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.2210 Get It

Abstract Background Left ventricular (LV) pressure overload and coronary artery disease, both of which are common in patients with coarctation of aorta (COA), are risk factors for LV diastolic dysfunction. Patients with COA may have aortic vasculopathy that can result in LV pressure overload even in the absence of hemodynamically significant COA. We therefore hypothesized that patients with COA (without hemodynamically significant COA) will have more LV diastolic dysfunction compared to controls. Methods Adult patients with COA (OA peak velocity <2 m/s) were matched 1:1 to patients without structural heart disease using propensity score method based on age, sex, body mass index, hypertension and blood pressure. The objective was to compare LV diastolic dysfunction (defined as E/e>2 standard deviations above age-specific normative values) between COA patients and controls. Results Of 204 COA and 204 control patients (age 35±12 years), COA patients had higher septal and lateral E/e' ratio (12±4 vs 9±4, p=0.009) and (10±3 vs 7±3, p<0.001), respectively. Compared to controls, the prevalence of LV diastolic dysfunction was higher in COA patients for every age group: <40 years (63% vs 13%, p<0.001); 41–60 years (87% vs 33%, p<0.001); age >60 years (82% vs 56%, p=0.076). Left ventricular mass index (LVMI) was the strongest determinant of E/e' (β=2.71 per 10 g/m2, standard error = 1.25, p<0.001). Conclusion LV diastolic dysfunction was common in COA patients, and the association with LVMI suggests that COA patients may have ongoing LV pressure overload in the absence of hemodynamically significant re-coarctation. Funding Acknowledgement Type of funding source: None